69957-83-1

Basic information

• Product Name: N-Ethyl-4-Chlorobenzylamine
• Synonyms: N-Ethyl-4-Chlorobenzylamine;4-Chloro-N-ethylbenzenemethanamine;(4-chlorobenzyl)ethylamine(SALTDATA: HCl);N-(4-Chlorobenzyl)ethanaMine
• CAS NO: 69957-83-1
• Molecular Formula: C₉H₁₂ClN
• Molecular Weight: 169.66
• Product Categories: Amines and Anilines
• Mol File: 69957-83-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 226.7 °C at 760 mmHg
• Flash Point: 90.9 °C
• Appearance: /
• Density: 1.063 g/cm³
• Vapor Pressure: 0.0808mmHg at 25°C
• Refractive Index: 1.525
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: N-Ethyl-4-Chlorobenzylamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Ethyl-4-Chlorobenzylamine(69957-83-1)
• EPA Substance Registry System: N-Ethyl-4-Chlorobenzylamine(69957-83-1)

Safety Data

• Hazardous Substances Data: 69957-83-1(Hazardous Substances Data)

Usage

Uses

N-Ethyl-4-chlorobenzylamine is used in preparation of heterocycles as angiotensin AT-2 receptor antagonists.

InChI:InChI=1/C9H12ClN/c1-2-11-7-8-3-5-9(10)6-4-8/h3-6,11H,2,7H2,1H3

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 75-05-8 acetonitrile 
• 75-04-7 ethylamine 
• 17972-03-1 [1-(4-Chloro-phenyl)-meth-(E)-ylidene]-ethyl-amine 
• 57058-33-0 N-(4-chlorobenzyl)acetamide 
• 64-17-5 ethanol 
• 444880-23-3 3-ethylamino-3-(4-chloro-phenyl)-2-nitro-propionic acid ethyl ester 
• 60-29-7 diethyl ether 
• 104-86-9 4-chlorobenzylamine 
• 80-40-0 ethyl ester of p-toluenesulfonic acid 
• 15481-55-7 4-Nitrobenzenesulfonic acid ethyl ester 
• 20443-71-4 ethyl chlorobenzene-p-sulphonate 
• 515-46-8 Ethyl benzenesulfonate 
• 26930-17-6 4-chloro-N-ethylbenzamide 

Downstream Products

• 1391073-93-0 1-[2-(3,5-dimethylphenyl)acetyl]-2-methyl-azetidine-2-carboxylic acid (4-chlorobenzyl)ethylamide 
• 209416-25-1 N-(4'-chlorophenylmethyl)-N-ethyl-4-(2,4,6-trimethyphenyl)-1-phthalazinamine 
• 93683-95-5 N⁶-(4-Chloro-benzyl)-N⁶-ethyl-pyrido[3,2-d]pyrimidine-2,4,6-triamine 
• 93683-83-1 3-Amino-6-[(4-chloro-benzyl)-ethyl-amino]-pyridine-2-carbonitrile 
• 93683-70-6 6-[(4-Chloro-benzyl)-ethyl-amino]-3-nitro-pyridine-2-carbonitrile 
• 55245-72-2 C₁₀H₁₁Cl₂NO 

Relevant articles and documents

Continuous flow synthesis of amines from the cascade reactions of nitriles and carbonyl-containing compounds promoted by Pt-modified titania catalysts

The effective design of an active and stable catalytic system was performed by a simple modification of a commercial titania with a low platinum loading. The prepared material was fully characterized by XRD, XPS, N2 adsorption-desorption measurements, ICP-MS, TEM and SEM analyses. Such techniques corroborated the successful incorporation of Pt onto the titania surface, without affecting its original structure, morphology and chemical nature. The obtained TiO2-Pt catalyst was effectively applied in several continuous flow reactions between nitriles and carbonyl containing compounds for amine preparation. Remarkably, conversion of levulinic acid, a biomass derived molecule, was achieved with outstanding conversion (87%) and selectivity (80%) to 1-ethyl-5-methylpyrrolidin-2-one. The catalytic system demonstrated a high stability through 120 min of reaction. Moreover, the effect of the nitrile was investigated by performing the reaction with benzonitrile and ethylcyanoacetate. The TiO2-Pt catalyst was also tested in the conversion of benzaldehyde, displaying remarkable results. The influence of substitution in the aromatic ring was investigated using p-nitro-benzaldehyde and p-chloro-benzaldehyde.

Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists

Monocyte infiltration is implicated in a variety of diseases including multiple myeloma, rheumatoid arthritis, and multiple sclerosis. C-C chemokine receptor 1 (CCR1) is a chemokine receptor that upon stimulation, particularly by macrophage inflammatory protein 1a (MIP-1a) and regulated on normal T-cell expressed and secreted (RANTES), mediates monocyte trafficking to sites of inflammation. High throughput screening of our combinatorial collection identified a novel, moderately potent CCR1 antagonist 3. The library hit 3 was optimized to the advanced lead compound 4. Compound 4 inhibited CCR1 mediated chemotaxis of monocytes with an IC50 of 20 nM. In addition, the compound was highly selective over other chemokine receptors. It had good microsomal stability when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CYP) inhibition. Pharmacokinetic evaluation of the compound in the rat showed good oral bioavailability.

Central cholinergic agents. I. Potent acetylcholinesterase inhibitors, 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es, based on a new hypothesis of the enzyme's active site

It has been suggested that the active site of acetylcholinesterase contains a hydrophobic binding site (HBS-1), which is closely adjacent to both the anionic and the esteratic sites. In this paper, we assumed that there exists another hydrophobic binding site (HBS-2), some distance removed from the anionic site. On this assumption, a new working hypothesis was proposed for the design of acetylcholinesterase inhibitors. A series of 2-[ω-[N-alkyl-N-(ω-phenylalkyl)amino]alkyl]-1H-isoindole-1,3(2H)-dion es was designed based on this hypothesis and tested for its inhibitory activities on acetylcholinesterase. Some in this series were revealed to be more potent than physostigmine. Optimum activity was found to be associated with a five carbon chain length separating the benzylamino group from the 1H-isoindole-1,3(2H)-dione (phthalimide) moiety. Quantitative study of substitution effect on the phthalimide moiety revealed that hydrophilic and electron-withdrawing groups enhance the activity.